Claims
- 1. A method for inhibiting angiogenesis, comprising administering to an animal a biologically effective amount of a pharmaceutically acceptable CXC chemokine composition that comprises an XXX-CXC chemokine other than PF4, the XXX-CXC chemokine lacking the amino acid sequence ELR (Glu Leu Arg).
- 2. The method of claim 1, wherein said CXC chemokine composition comprises IP-10.
- 3. The method of claim 1, wherein said CXC chemokine composition comprises MIG.
- 4. The method of claim 1, wherein said CXC chemokine composition comprises an ELR-CXC chemokine modified to remove or replace the amino acid sequence ELR.
- 5. The method of claim 4, wherein said CXC chemokine composition comprises an IL-8 polypeptide modified to remove or replace the amino acid sequence ELR.
- 6. The method of claim 5, wherein said CXC chemokine composition comprises an IL-8 polypeptide in which the amino acid sequence ELR has been replaced with the amino acid sequence TVR.
- 7. The method of claim 5, wherein said CXC chemokine composition comprises an IL-8 polypeptide in which the amino acid sequence ELR has been replaced with the amino acid sequence DLQ.
- 8. The method of claim 1, wherein said CXC chemokine composition comprises an XXX-CXC chemokine prepared by expressing a CXC chemokine gene in a recombinant host cell and collecting the expressed CXC chemokine protein.
- 9. The method of claim 1, wherein said CXC chemokine composition comprises an XXX-CXC chemokine prepared by automated peptide synthesis.
- 10. The method of claim 1, wherein said CXC chemokine composition comprises a gene that expresses an XXX-CXC chemokine other than PF4.
- 11. The method of claim 10, wherein said CXC chemokine composition comprises a gene that expresses IP-10.
- 12. The method of claim 10, wherein said CXC chemokine composition comprises a gene that expresses MIG.
- 13. The method of claim 10, wherein said CXC chemokine composition comprises a gene that expresses an ELR-CXC chemokine modified to remove or replace the amino acid sequence ELR.
- 14. The method of claim 13, wherein said CXC chemokine composition comprises a gene that expresses an IL-8 polypeptide modified to remove or replace the amino acid sequence ELR.
- 15. The method of claim 14, wherein said CXC chemokine composition comprises a gene that expresses an IL-8 polypeptide in which the amino acid sequence ELR has been replaced with the amino acid sequence TVR or the amino acid sequence DLQ.
- 16. The method of claim 1, wherein said animal is a human subject.
- 17. A method for inducing angiostasis, comprising preparing a pharmaceutically acceptable CXC chemokine composition that comprises an XXX-CXC chemokine other than PF4, the XXX-CXC chemokine lacking the amino acid sequence ELR, and administering said composition to an animal in an amount effective to induce angiostasis.
- 18. A method for inhibiting angiogenesis, comprising administering to an animal an effective inhibitory amount of a pharmaceutically acceptable composition comprising a biological agent that inhibits an ELR-CXC chemokine other than IL-8, the ELR-CXC chemokine including the amino acid sequence ELR.
- 19. The method of claim 18, wherein said composition comprises a biological agent that inhibits ENA-78, GCP-2, CTAP-III, NAP-2 or βTG.
- 20. The method of claim 19, wherein said composition comprises an antibody that binds to ENA-78, GCP-2, CTAP-III, NAP-2 or βTG.
- 21. The method of claim 19, wherein said composition comprises an antisense nucleic acid molecule that binds to a nucleic acid sequence that encodes ENA-78, GCP-2, CTAP-III, NAP-2 or βTG.
- 22. The method of claim 19, wherein said composition comprises a biological agent that inhibits ENA-78.
- 23. The method of claim 19, wherein said composition comprises a biological agent that inhibits GCP-2.
- 24. The method of claim 19, wherein said composition comprises a biological agent that inhibits CTAP-III.
- 25. The method of claim 19, wherein said composition comprises a biological agent that inhibits NAP-2.
- 26. The method of claim 19, wherein said composition comprises a biological agent that inhibits βTG.
- 27. A method for stimulating angiogenesis, comprising administering to an animal a biologically effective amount of a pharmaceutically acceptable CXC chemokine composition that comprises an ELR-CXC chemokine other than IL-8, the ELR-CXC chemokine including the amino acid sequence ELR.
- 28. The method of claim 27, wherein said CXC chemokine composition comprises ENA-78.
- 29. The method of claim 27, wherein said CXC chemokine composition comprises GCP-2.
- 30. The method of claim 27, wherein said CXC chemokine composition comprises CTAP-III.
- 31. The method of claim 27, wherein said CXC chemokine composition comprises NAP-2.
- 32. The method of claim 27, wherein said CXC chemokine composition comprises βTG.
- 33. The method of claim 27, wherein said CXC chemokine composition comprises an XXX-CXC chemokine modified to contain the amino acid sequence ELR.
- 34. The method of claim 33, wherein said CXC chemokine composition comprises MIG modified to contain the amino acid sequence ELR.
- 35. The method of claim 27, wherein said CXC chemokine composition comprises a CXC chemokine prepared by expressing a CXC chemokine gene in a recombinant host cell and collecting the expressed CXC chemokine protein.
- 36. The method of claim 27, wherein said CXC chemokine composition comprises a CXC chemokine prepared by automated peptide synthesis.
- 37. The method of claim 27, wherein said CXC chemokine composition comprises a gene that expresses ENA-78, GCP-2, CTAP-III, NAP-2, βTG or an XXX-CXC chemokine modified to contain the amino acid sequence ELR.
- 38. A method for stimulating angiogenesis, comprising administering to an animal an effective inhibitory amount of a pharmaceutically acceptable composition comprising a biological agent that inhibits an XXX-CXC chemokine other than PF4, the XXX-CXC chemokine lacking the amino acid sequence ELR.
- 39. The method of claim 38, wherein said composition comprises a biological agent that inhibits IP-10 or MIG.
- 40. The method of claim 39, wherein said composition comprises a biological agent that inhibits IP-10.
- 41. The method of claim 39, wherein said composition comprises a biological agent that inhibits MIG.
- 42. The method of claim 39, wherein said composition comprises an antibody that binds to IP-10 or MIG.
- 43. The method of claim 39, wherein said composition comprises an antisense nucleic acid molecule that binds to a nucleic acid sequence that encodes IP-10 or MIG.
- 44. A method for promoting wound-healing, comprising contacting a wound site of an animal with a biologically effective amount of a CXC chemokine composition comprising an ELR-CXC chemokine other than a GRO protein, the ELR-CXC chemokine including the amino acid sequence ELR.
- 45. The method of claim 44, wherein said composition comprises IL-8, ENA-78, GCP-2, CTAP-III, NAP-2, βTG or an XXX-CXC chemokine modified to contain the amino acid sequence ELR.
- 46. The method of claim 45, wherein said composition comprises IL-8 or ENA-78.
- 47. The method of claim 44, wherein said animal has a skin, gastric or duodenal ulcer.
- 48. An ophthalmic formulation comprising an ophthalmically acceptable diluent and a biologically effective amount of a CXC chemokine composition comprising an XXX-CXC chemokine other than PF4, the XXX-CXC chemokine lacking the amino acid sequence ELR.
- 49. A wound dressing or bandage that includes a biologically effective amount of a CXC chemokine composition comprising an ELR-CXC chemokine other than a GRO protein, the ELR-CXC chemokine including the amino acid sequence ELR.
- 50. The wound dressing or bandage of claim 49, further defined as a hydrocolloid wound dressing.
- 51. A method for characterizing a tumor, comprising obtaining a sample from said tumor and testing the sample for the presence of a cytokine, the cytokine selected from the group consisting of GROα, GROβ, GROγ, ENA-78, GCP-2, CTAP-III, NAP-2, βTG and IL-10, wherein an increased amount of said cytokine is indicative of a tumor with increased angiogenic activity.
- 52. The method of claim 51, comprising testing said sample for the presence of said cytokine protein.
- 53. The method of claim 51, comprising testing said sample for the presence of a nucleic acid that encodes said cytokine.
- 54. The method of claim 51, comprising testing the sample for the presence of a first cytokine selected from the group consisting of GROα, GROβ and GROγ; a second cytokine selected from the group consisting of CTAP-III, NAP-2 and βTG; and a third cytokine selected from the group consisting of ENA-78, GCP-2 and IL-10; wherein an increased amount of said first, second and third cytokines is indicative of a tumor with increased angiogenic activity.
- 55. The method of claim 51, further comprising testing the sample for the presence of IL-8, wherein an increased amount of IL-8, in addition to an increased amount of said cytokine, is indicative of a tumor with increased angiogenic activity.
Government Interests
[0001] The U.S. Government owns rights in the present invention pursuant to grant numbers HL50057, HL39926 and HL31693 from the National Institutes of Health.
Divisions (1)
|
Number |
Date |
Country |
Parent |
08468819 |
Jun 1995 |
US |
Child |
09213383 |
Dec 1998 |
US |
Continuations (1)
|
Number |
Date |
Country |
Parent |
09213383 |
Dec 1998 |
US |
Child |
10104755 |
Mar 2002 |
US |